Precision BioSciences to Participate in the Truist Securities 2021 Life Sciences Virtual Series
Search jobs Precision BioSciences to Participate in the Truist Securities 2021 Life Sciences Virtual Series DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz, Ph.D., Chief Scientific Officer and Co-Founder will participate in a fireside chat at the Truist Securities 2021 Life Sciences Virtual Series. Details for the fireside chat are below: The Truist Securities 2021...
Source: pharmiweb.com